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Approximately half of autism spectrum disorder (ASD) individuals suffer from comorbid 
intellectual disabilities (IDs). Oxytocin (OXT) receptors are highly expressed in temporal lobe 
structures and are likely to play a modulatory role in excitatory/inhibitory balance, at least 
based on animal model findings. Thus, it is feasible that in the highly representative group 
of Kanner-type ASD subjects, OXT could have a beneficial effect on social communication 
and social interaction. The aim of this pilot study is to investigate the feasibility and adverse 
events, such as epilepsy, of the long-term administration of intranasal OXT for adolescent 
and adult ASD subjects with ID because such patients frequently have seizures. We also 
addressed the question on how to scale the OXT effects to the core symptoms of social 
deficits because of the relative difficulty in obtaining objective measurements. Twenty-nine 
males (aged 15–40  years old) participated in a randomized, double-blind, and place-
bo-controlled crossover study (each for 8 weeks) with OXT (16 IU/day). Except for seizures 
experienced by one participant, other serious adverse events did not occur. The primary 
and secondary outcomes measured using the Childhood Autism Rating Scale and several 
standard scales, respectively, revealed no difference between the OXT and placebo groups. 
Instead, in an exploratory analysis, the social interactions observed in the play sessions or 
in daily life were significantly more frequent in the initial half period in the OXT-first arm of the 
crossover trial. There were also significant correlations between the plasma OXT concen-
tration and subscale scores for irritability on the Aberrant Behavior Checklist. In conclusion, 
this pilot study demonstrates that long-term administration of intranasal OXT is tolerable in 
a representative cohort of ASD individuals with ID and suggests that future multicenter trials 
of OXT are warranted and should include measurements of reciprocal social interactions 
based on daily life under closer surveillance for epilepsy. Trial registration: UMIN000007250.
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inTrODUcTiOn
Autism spectrum disorder (ASD) is a neurodevelopmental and 
life-long syndrome with multiple etiologies, different phenotypes, 
and a high prevalence, estimated at 0.62–2% (1–3). The core 
symptoms of ASD have consisted of social and communication 
impairments and repetitive behaviors since the earliest reports by 
Leo Kanner in 1943 and Hans Asperger in 1944 (4–6). The clini-
cal domain of social deficits, expressed symbolically as “autism,” 
results in serious maladjustment in individuals with ASD in their 
daily lives (7). The societal domain of social deficits, conceptual-
ized as theory of mind impairments (8), addresses critically 
interdisciplinary issues, including social psychology (9) and 
philosophy (10). In clinical settings, there are no effective treat-
ments for the various symptoms of ASD, except for irritability, 
which can be alleviated by risperidone (11) or aripiprazole (12). 
As for social deficits, little to no pharmacological treatments have 
been proven to be effective (13, 14), although recent studies sug-
gest the efficacy of risperidone for social disabilities based on the 
Aberrant Behavior Checklist (ABC) subscale of social withdrawal 
(15, 16) and the promising candidate neuroendocrine hormone 
oxytocin [OXT (17, 18)].
The results of four clinical trials on short-term OXT 
administration performed over the last decade (19–22) and a 
meta-analysis of a single administration suggest that OXT has 
significant benefits compared with a placebo in the treatment of 
ASD, although it has a moderate effect size (Cohen’s d = 0.57) 
(23). Notably, social deficits have been reported to be relieved by 
OXT administration (20–22, 24–26). Over the last 5 years, nearly 
20 clinical trials have been registered to investigate whether 
long-term OXT treatment is beneficial. Among them, two recent 
studies have yielded inconsistent results: in one study, while no 
effect was found on the primary outcome, the three secondary 
outcomes were significantly improved by OXT (27); by contrast, 
in the other report, none of the measures showed any significant 
differences between OXT and the placebo (28). Interestingly, the 
“reading the mind in the eyes” test revealed significantly favorable 
responses in the social deficits of ASD subjects following OXT 
administration (27).
Approximately 56% of ASD individuals suffer from a comor-
bid intellectual disability (ID) (29). In addition, the prevalence 
of epilepsy has been estimated to be 46% in ASD patients with 
low intelligence quotient (IQ) (30). Because these patients have 
rarely been subjects in recent biological and clinical studies 
(31), whether they would receive benefits from OXT remains 
unknown. In addition, OXT receptors are highly expressed in 
the temporal lobe of the brain and are likely to play a modula-
tory role in maintaining the excitatory/inhibitory balance (32), 
at least based on results of animal model studies (32, 33). Thus, it 
is feasible that in the highly representative group of Kanner-type 
ASD subjects, OXT could have a beneficial effect on social com-
munication and interaction. Therefore, an OXT clinical trial 
in this important population of individuals with the so-called 
Kanner type of ASD is warranted (5). Here, our first aim is to 
investigate the potential therapeutic effects of intranasal OXT 
administration on a variety of symptoms or adverse effects, 
including seizures, in adolescents and adults with ASD and a 
comorbid ID. Another aim is to determine which measure-
ments are applicable for such individuals because it is relatively 
difficult to obtain objective measurements using computer 
tests and brain imaging instruments in which the patients have 
to correctly respond to instructions during examinations. To 
address this difficulty, we conducted an exploratory analysis 
of daily-life behaviors from a list of real-life events of recipro-
cal social interactions that were obtained from the patients’ 
caregivers and an involved doctor, in addition to primary and 
secondary outcomes measured by existing standard scales 
that are typically applied to ASD patients. We also measured 
the plasma OXT concentration of ASD participants with ID to 
examine the relationship between the OXT concentration and 
behavioral indexes.
MaTerials anD MeThODs
The CONSORT checklist and protocol for this study are available 
as Datasheets S1 and S2 in Supplementary Material, respectively.
ethics statement
This study was approved by the institutional review board in the 
Innovative Clinical Research Center of Kanazawa University 
Hospital, Japan [Approval No. 2011-045 (5749)]. The study was 
performed according to the Declaration of Helsinki and the 
Ethical Guidelines for Clinical Studies of the Ministry of Health, 
Labour, and Welfare of Japan. Following a complete explanation 
of the study, all of the caregivers of the participants provided 
written informed consent, and participants provided written 
informed assent if they could read and understand the informed 
assent form (Datasheet S3 in Supplementary Material), which we 
composed in concise and understandable language.
study Design and setting
We designed a pilot, randomized, double-blind, and placebo-
controlled crossover study conducted from February 2012 to 
October 2013. The study was registered with the University 
Hospital Medical Information Network (UMIN) Clinical Trials 
Registry (number UMIN000007250; https://upload.umin.ac.jp/
cgi-open-bin/ctr/ctr.cgi?function=search&action=input&lang
uage=E). The study was conducted in the outpatient setting of 
the Department of Child and Adolescent Psychiatry of Kanazawa 
University Hospital in Kanazawa, Japan.
The two treatment periods were combined into one period 
(16 weeks) by setting the beginning of the second treatment period 
as the baseline. During the initial study design, we thought that 
crossover would provide complete results; we expected the effect 
of OXT would appear in the OXT arm and not in the placebo 
arm. In the second term, we again expected that the OXT effect 
would appear in the OXT arm in which little-to-no effects were 
observed during the initial placebo treatment and that the OXT 
effect would disappear gradually in the placebo period. Since no 
information was available for setting the length of the washout 
period in 2012, the two phases were conducted consecutively 
without the washout period.
FigUre 1 | schema of the study. Prior to study enrollment, participants, 
and their caregivers visited Kanazawa University Hospital every 2 weeks 
during the preparatory period. Each visit consisted of a play session with a 
participant and an interview session with the caregivers. After the study 
began, the participants and caregivers visited the hospital eight times every 
2 weeks and engaged in the same activities.
January 2016 | Volume 7 | Article 23
Munesue et al. Oxytocin for ASD with Intellectual Disabilities
Frontiers in Psychiatry | www.frontiersin.org
Participants
Eligible participants were male adolescents and adults aged 
15–45 years. They had been diagnosed with a pervasive devel-
opmental disorder, as defined by the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition, text revision (DSM-
IV-TR) (34). The diagnoses of all of the participants were confirmed 
using the Diagnostic Interview for Social and Communication 
Disorders, eleventh edition (35), by the first author, who is certi-
fied. All of the participants were required to have an ID measured 
as an IQ < 70 on the Tanaka–Binet Intelligence Scale [a Japanese 
version of the Stanford–Binet Intelligence Scale (36)].
The exclusion criteria included a concomitant or previous his-
tory of severe polydipsia, water intoxication (37–39) or substance 
dependence, or a previous history of traumatic brain injury with 
a loss of consciousness for more than 5 min.
We have previously observed behaviorally favorable changes in 
several outpatients with ASD and a comorbid ID who received over-
the-counter OXT (40). We estimated that approximately 60% of 
these ASD patients benefited from OXT. Accordingly, we tentatively 
estimated a sample size of 30 in a crossover design. We expected 
that we would be able to recruit 30 participants among 150 or more 
patients with ASD who regularly visited the Kanazawa University 
Hospital to receive drug therapies or psychosocial interventions. 
Fourteen candidates were recruited from a clinics specializing in 
ASD and the University of Fukui Hospital in neighboring towns.
randomization and Blinding
Eligible participants completed baseline evaluations and were 
randomly assigned at a 1:1 ratio to receive either 8 IU of OXT twice 
per day or a matching placebo twice per day for 8 weeks during 
the first treatment period (Figure 1). The participants were then 
crossed over, without washout, to the other treatment for 8 weeks 
during the second treatment period. The two treatment periods 
were followed by an 8-week posttreatment period without treat-
ment administration. We adopted a crossover design because of 
ethical considerations. Randomization was centralized, and a 
computer-generated list with random block sizes of six was used 
in the Innovative Clinical Research Center, Kanazawa University 
Hospital. The study staff, participants, and their caregivers did not 
have access to the allocation sequence until the end of the study.
Treatments
Nasal spray bottles were prepared by two pharmacists in the 
Kanazawa University Hospital. Syntocinon (Novartis, Huningue, 
France; 5 ml per bottle) in the original bottles was transferred to 
sterile nasal spray bottles (Oono, Co., Ltd., Tokyo, Japan). One 
puff of the bottle was confirmed to contain 4  IU of OXT. An 
identical bottle was prepared containing 5  ml of placebo, con-
sisting of all of the ingredients in Syntocinon, except OXT. The 
participants practiced puffing the placebo into their nostrils with 
the assistance of their caregivers for 2–4  weeks at their homes 
prior to the commencement of the study.
Play sessions
Prior to the study, 20-min play sessions were held between each 
subject and the first author every 2 weeks for 2–6 months in the 
playroom of our hospital (the preparatory period; Figure 1). We 
aimed for the ASD participants with ID to become familiar with 
the study setting, electrocardiography, and blood collection in 
the hospital during these prestudy sessions. We also carefully 
observed the participants’ behaviors.
Each participant visited the hospital every 2  weeks during 
the study. Each visit included a 20-min play session, which was 
recorded by two video cameras set up diagonally in the play-
room, and an interview session with the caregivers (Figure 1). 
During the play sessions, the first author sat or stood close to 
each participant, observed him, and sometimes addressed him 
or showed him toys. The first author did not pressure a social 
interaction with the participants; instead, he took a passive role 
to be spontaneously approached by the participant.
Outcomes
The treatment adherence rate was ascertained by a treatment 
diary in which the spraying times in the morning and evening 
were recorded by the caregivers.
assessment of harm
The caregivers reported all of the events using a questionnaire devel-
oped for this study at each visit (Datasheet S4 in Supplementary 
Material). We measured the body weight, blood pressure, and 
pulse rate every 4 weeks. Blood work, urinalysis, and electrocardi-
ography were performed every 4 weeks. The blood work included 
assessments of the blood counts, electrolytes, renal and liver func-
tion, and osmolality. Urine osmolality was measured in addition 
to routine urinalysis assessments. Although these measurements 
would have been informative, the participants were not monitored 
with electroencephalography, magnetoencephalography, mag-
netic resonance imaging, and computed tomography because it 
was difficult to attach probes to the patients’ heads and to get them 
to lie down on the bed without movement.
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Primary Outcome Measure
A change in the primary outcome was evaluated using the 
Childhood Autism Rating Scale (CARS) (41).
secondary Outcome Measures
The secondary outcomes consisted of changes in scores evaluated 
using the ABC (16), the Clinical Global Impressions – Improvement 
(CGI-I) scale, and the Global Assessment of Functioning (GAF) 
(34, 42). The Interaction Rating Scale Advanced (IRSA) (43, 44) was 
used for measuring six domains in social interaction. The patients’ 
social behavior was assessed by inspecting the videos captured by 
two fixed-angle cameras in the playroom in the Kanazawa University 
Hospital. As for CGI-I, we regarded a participant as a responder 
only when he was categorized as clinically improved (CGI-I ≤ 2).
exploratory Outcomes: real-life 
assessments of social interactions
From the beginning of this study, we noticed the necessity of a special 
analysis for changes in outcomes of social deficits as a core symptom 
of ASD and in plasma OXT levels in our patients with ID. The pos-
sibility of an assessment of social interaction based on medical charts 
had been included in the original protocol (lines 8–17 in page 16 
in Datasheet S2 in Supplementary Material), although we did not 
describe the exact methods to analyze the OXT effects on social 
interaction and the OXT concentrations. However, we decided to use 
the recordings in the medical chart after 1 month from start of statis-
tical analyses because details of the participants’ behaviors obtained 
during an interview session with the caregivers and during the play 
sessions with participants were entered into the medical charts by 
the first author. Details of the participants’ behaviors in their daily 
life since the last visit were freely recounted by caregivers during the 
interview sessions and were entered into the medical charts by the first 
author (Figure S1 in Supplementary Material). These descriptions 
included various episodes that had not been previously observed 
for the participants. For example, a mother reported the following: 
“My son (40 years old with profound ID) pours hot Japanese tea in a 
teacup from a teapot for me upon my request. Usually, he leaves the 
teacup standing. The other day, however, further handed it to me. 
That was his first behavioral change. I was very happy by this.” These 
episodes may merely refer to unintentional observations by the first 
author or free statements of recollection by caregivers. Moreover, the 
documents recorded by the first author varied in the amount and 
quality for each participant and for each visit. However, we believe 
that there may be meaningful episodes, such as the above example, 
in these fragmentary descriptions.
After this clinical trial and observation was completed, all 
data, including the medical charts, were fixed and controlled by 
the clinical trial control center. After competing of analyses of 
primary and secondary outcomes (except for IRSA), social inter-
action from the medical chart were selected by the two coauthors 
(Noriyuki Takeuchi, a sociologist, and Yui Miura, a psychologist). 
They were involved only in the data analysis of this study and 
never met the participants or their caregivers. The two researchers 
inspected and examined the all documents for 29 participants that 
were anonymously printed from the medical chart of each partici-
pant for 3 days in the first week and repeated twice in the following 
week. Subsequently, they independently sampled episodes that 
were identified as reciprocal social interactions. The definition of 
“reciprocal social interaction” refers to descriptions determined 
as indicating the existence of interpersonal exchanges between a 
participant and the first author or caregivers. We counted these 
episodes at each visit and then scored them dichotomously as 
plus (number ≥ 1) or minus (number = 0) an index of real-life 
social interactions at each visit. The intrarater reliability was tested 
three times with >90% reliability, and interrater reliability was 
approximately 85%. Reliability was calculated by the Fisher’s exact 
probability test. We then used these data as exploratory outcomes.
Plasma OXT concentrations
The OXT immunoreactivity levels on unextracted samples were 
quantified by an OXT enzyme immunoassay kit (Catalog No. 
ADI-900-153, Assays Designs, MI, USA) as previously described 
(40, 45). Blood was collected between 2 and 5 p.m. every 4 weeks. 
The participants were instructed to abstain from food for 2 h prior 
to blood collection.
evaluators of each Outcome
The scores on the CARS, the CGI-I scale, and the GAF and adverse 
events and treatment adherence were evaluated by the first author. 
The ABC was noted by the caregivers. The IRSA was assessed 
by a coauthor (Tokie Anme) using videotaped images. Real-life 
assessments of social interactions were rated by the two coauthors 
(Noriyuki Takeuchi and Yui Miura). Figure S1 in Supplementary 
Material presents the interval of each assessment. The plasma OXT 
concentration was assayed by a coauthor (Haruhiro Higashida).
statistical analysis
The comparisons of interest were the sequential differences 
between the two treatment groups in seven measurements. In 
our crossover study, we employed a generalized mixed regression 
analysis, with treatment (OXT or placebo), time (each visit), and 
order (OXT then placebo or placebo then OXT) as the independ-
ent factors. The two treatment periods were combined into one 
period (8 weeks) by setting the beginning of the second treatment 
period as the baseline. When data of variables in participant 
characteristics were significantly different between the OXT-first 
group and the placebo-first group, the variables were included 
as covariates in the analysis. When a significant order effect was 
identified, additional generalized mixed regression analyses with 
treatment (OXT or placebo) and time (each visit) as the independ-
ent factors were applied for only the first treatment period. All of 
the statistical analyses were performed using Statistical Package 
for the Social Sciences (SPSS) software, version 21 (IBM Japan, 
Tokyo, Japan). We planned this pilot study to show the feasibility 
of conducting a larger study in the future and to collect data to 
help optimize its design. Because of the small sample size (i.e., low 
statistical power), the significance level was set at 0.05, and we did 
not employ correction for multiple comparisons.
resUlTs
As shown in Figure 2, 15 patients were excluded from the initial 44 
patients recruited. Thus, we enrolled 29 participants, and 28 were 
TaBle 1 | Participant characteristics by treatment arm.
characteristics Oxytocin first Placebo first all participants
(N = 15) (N = 14) (N = 29)
Age (years; 
mean ± SD)
22.6 ± 4.3 22.4 ± 7.4 22.5 ± 5.9
Intelligence quotient
  Measurable 
(mean ± SD)
24.9 ± 13.2 37.5 ± 13.9 32.6 ± 14.7
 Immeasurable 8 (53.3%) 3 (21.4%) 11 (37.9%)
Intellectual disabilities
 Mild 1 (6.7%) 2 (14.3%) 3 (10.3%)
 Moderate 0 (0%) 6 (42.9%) 6 (20.7%)
 Severe 3 (20%) 1 (7.1%) 4 (13.8%)
 Profound 11 (73.3%) 5 (35.7%) 16 (55.2%)
Psychotropic 
medications
12 (80%) 10 (71.4%) 22 (75.9%)
Epilepsy 4 (26.7%) 3 (21.4%) 7 (24.1%)
Behavioral 
assessments
 CARS (mean ± SD) 43.1 ± 3.0 41.4 ± 4.5 42.3 ± 3.8
 ABC (mean ± SD)
 Irritability 11.9 ± 9.4 17.4 ± 11.7 14.6 ± 10.7
 Lethargy 12.8 ± 11.1 12.6 ± 6.1 12.7 ± 8.9
 Stereotypic behavior 7 ± 5.9 5.2 ± 5.8 6.1 ± 5.8
 Hyperactivity 13.9 ± 9.4 16 ± 10.3 14.9 ± 9.7
 Inappropriate speech 4.9 ± 3.0 7 ± 3.7 5.9 ± 3.5
 Total 50.3 ± 28.0 58.3 ± 26.8 54.2 ± 27.2
 GAF (mean ± SD) 31.3 ± 6.0 35.6 ± 9.7 33.5 ± 8.1
 IRSA (mean ± SD) 165.6 ± 28.8 189.1 ± 32.6 177.3 ± 32.5
Plasma OXT 
concentration (pg/
ml; mean ± SD)
217.6 ± 165.2 306.3 ± 341.3 263.6 ± 270.0
CARS, Childhood Autism Rating Scale; ABC, Aberrant Behavior Checklist; GAF, 
Global Assessment of Functioning; IRSA, Interaction Rating Scale Advanced; OXT, 
oxytocin.
Details for all of the participants are summarized in Table S1 in Supplementary Material.
FigUre 2 | cOnsOrT 2010 flow diagram.
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able to complete the study. One participant experienced seizures 
during the first and second treatment periods and discontinued 
the study in the second period.
Table  1 summarizes the baseline characteristics of the allo-
cated participants. All of the participants were diagnosed as hav-
ing autistic disorder according to the DSM-IV-TR. No significant 
differences were found between the two groups with regards to 
age, psychotropic medications, or epilepsy. The participants were 
aged 15–40 years (mean ± SD = 22.5 ± 5.9) and had IQs ranging 
from immeasurable to 59 (mean ± SD = 32.6 ± 14.7). None of 
the participants had histories of common medical conditions 
associated with syndromic ASD, such as tuberous sclerosis. 
Seven participants (24.1%) had comorbid stable epilepsy, and one 
subject suffered from recurrent attacks once or twice per year. 
Twenty-two participants (75.9%) received psychotropic medica-
tions at stable doses during the 3 weeks prior to randomization. 
We did not observe any significant differences in the behavioral 
assessments using the CARS, ABC, GAF, and IRSA between the 
two groups (Table  1). However, the proportion of the severity 
of ID was significantly different between the OXT-first and the 
placebo-first groups (P = 0.013, Fisher’s exact test). We included 
the variable as covariate in the following analysis. More detailed 
characteristics of each participant are presented in Table S1 in 
Supplementary Material.
The mean values of treatment adherence ranged from 96.3 
to 99.7% in the OXT-first group and from 97.1 to 99.5% in the 
placebo-first group during the 16-week treatment period (Table S2 
in Supplementary Material). The intranasal sprayings were admin-
istered immediately after breakfast and dinner to all participants.
assessment of harms
All of the adverse events reported by family members 
according to the questionnaire are listed in Table S3 in 
Supplementary Material. There were no differences in the 
number of adverse events between the OXT and placebo 
arms. No significant differences occurred in body weight, 
diastolic blood pressure, systolic blood pressure, and pulse 
rate between the two groups (Table S4 in Supplementary 
Material). No difference was observed between the results of 
the blood work and urinalysis or electrocardiography of the 
two groups (data not shown).
One participant (22 years old) experienced a seizure on the 
33rd day of the first OXT treatment period. On the eighth day 
of the second treatment period, he had another seizure and 
FigUre 3 | sequential changes in the outcome measures. (a) The Childhood Autism Rating Scale (CARS). (B) The Clinical Global Impressions – Improvement 
scale (CGI-I). (c) The Aberrant Behavior Checklist (ABC). (D) The Global Assessment of Functioning (GAF). (e) The Interaction Rating Scale Advanced (IRSA).  
(F) Plasma oxytocin (OXT) concentrations. Solid and dashed lines indicate the OXT-first and placebo (PLB)-first groups. Black and white bars indicate the first 
treatment period and second treatment period, respectively (8 weeks for each period). Error bars indicate the SEM values. Response rates in the CGI-I show the 
percentages of participants assessed at 1 (very much improved) or 2 (much improved). There were no significant main effects of the treatment on any of the 
outcome measures.
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discontinued the study, although he had received antiepileptic 
medications from the age of 5 years old and had not suffered a sei-
zure since the age of 15 years old. His treatment adherence to OXT 
and antiepileptics was excellent. He did not exhibit hyponatremia 
during the study. Thereafter, seizures occurred repeatedly two or 
three times a month, although the doses of his antiepileptics had 
been increased. Another participant with stable epilepsy experi-
enced a seizure on the 36th day of the posttreatment period. This 
participant was allocated to receive OXT administration in the 
second treatment period. We postulate that this seizure could be 
attributed to his forgetting to take antiepileptic medication for 2 
or 3 days prior to the seizure.
Primary Outcome Measure
There were significant main effects for time and order on the 
CARS. However, there was no main effect of treatment (Figure 3A; 
Table S5 in Supplementary Material). Furthermore, there was a 
significant main effect for time but not for treatment during the 
first treatment period.
secondary Outcome Measures
There were no main effects of treatment on the CGI-I scale 
(Figure  3B), the ABC (Figure  3C), the GAF (Figure  3D), the 
IRSA (Figure 3E), or the plasma OXT concentrations (Figure 3F). 
All of the raw data from these measures are shown in Table S5 in 
Supplementary Material.
As the IRSA is based on retrospective inspection of behavior, 
it was possible to analyze patients’ behavior by replaying movies 
monitored by digital video cameras. No significant difference 
in frequencies and duration of social interaction, such as 
eye gaze, expressivity, assertiveness, and responsiveness, was 
detected between the OXT and placebo arms, suggesting that 
patients’ behaviors in the playroom are not improved by OXT. 
Improvement of repetitive behavior or focused stereotypies 
in the playroom was not obvious after OXT treatment by the 
medical doctor (in CGI). Therefore, we decided to analyze the 
patients’ behaviors in detail using the records in the medical 
charts, according to the protocol.
assessment of social interactions in Daily 
life
Table S6 in Supplementary Material lists examples of episodes 
that were regarded as reciprocal social interactions. We present 
the changes in the percentages of participants with at least 
one episode in Figure 4A (see also Table S5 in Supplementary 
Material). There were significant main effects for time and order, 
FigUre 4 | sequential changes in the percentages of participants with at least one episode of social interaction. (a–c) Percentages indicate the 
proportions of all participants who had at least one episode that was regarded as reciprocal social interactions every 2 weeks. Solid and dashed lines indicate the 
oxytocin (OXT)-first and the placebo (PLB)-first groups. Black and white bars indicate the first treatment period and second treatment period, respectively. (a) There 
were significant main effects for time and order, but not for treatment (P = 0.090). However, during the first treatment period, there was a significant main effect of 
treatment (P = 0.029). Moreover, there was a significant interaction between treatment and time (P = 0.041). (B) Sequential changes of episodes regarded as 
reciprocal social interactions in participants (n = 20) with plasma OXT concentrations below 250 pg/ml. There were significant main effects for time and order, but 
not for treatment (P = 0.109). However, during the first treatment period, there was a significant main effect of treatment (P = 0.028). Moreover, there was a 
significant interaction between treatment and time (P = 0.038). (c) The same as in B, except participants (n = 7) with OXT concentrations over 250 pg/ml. A 
generalized mixed regression analysis not including ID showed no significant main effect of treatment (P = 0.983) during the first treatment period. (D,e) Scatter 
plots portraying the relationships between plasma OXT concentrations and baseline scores on the Aberrant Behavior Checklist (ABC) (D) and the ABC irritability 
subscale (e). The slopes of the dotted linear regression lines indicate a correlation trend [P = 0.079 (D)] and a significant correlation [P = 0.020 (e)] in all of the 
participants.
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but not for treatment (P  =  0.090). However, during the first 
treatment period, there was a significant main effect of treatment 
(P = 0.029). Moreover, there was a significant interaction between 
treatment and time (P = 0.041).
Plasma Oxytocin levels
We assessed whether reciprocal social interactions produced by 
OXT differed in rates, depending on the plasma OXT concentra-
tion. The participants were divided into two groups based on 
the baseline plasma OXT concentration (above or below 250 pg/
ml, an appropriate average value for all of the participants) 
(Figures 4B,C). In the ASD participants with low plasma OXT 
(below 250  pg/ml, n =  20), there were significant main effects 
for time and order, but not for treatment (P = 0.109). However, 
during the first treatment period, a significant main effect of 
treatment was observed (P  =  0.028). Moreover, there was a 
significant interaction between treatment and time (P = 0.038). 
In the participants with high plasma OXT (above 250  pg/ml, 
n = 7), there was a significant main effect for order, but not for 
treatment (P = 0.805) and time. During the first treatment period, 
data from seven participants were too small to analyze using a 
generalized mixed regression model including ID as a covariate. 
A generalized mixed regression analysis not including ID showed 
no significant main effect of treatment during the first treatment 
period (P = 0.983).
There was a trend toward a correlation between the baseline 
OXT concentrations and baseline scores on the ABC (P = 0.079; 
Figure 4D), but not for the CARS, GAF, and IRSA. There were also 
significant correlations between the baseline OXT concentrations 
and baseline scores on the ABC irritability subscale (P = 0.020; 
Figure 4E).
DiscUssiOn
To the best of our knowledge, this is the first randomized study 
of OXT that enrolled male patients with ASD and ID. Although 
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the participants were of a wide range of ages (from 15 to 40 years 
old) and intellectual levels, the results suggest that long-term 
clinical trials of intranasal OXT administration are acceptable 
for ASD individuals with ID. In this study, the outcomes based 
on conventional measurements demonstrated no significant 
differences between OXT and the placebo treatments. However, 
we found that the reciprocal social interactions exhibited by the 
participants in their daily life, as noticed by their caregivers or in 
play sessions observed by a researcher, were significantly more 
frequent during the period of OXT administration than placebo. 
In addition, lower levels of plasma OXT at baseline predicted 
significant increases in social interactions, and there were sig-
nificant correlations between the baseline OXT concentrations 
and scores on the ABC irritability subscale. False control rates 
were not taken into consideration because this is the pilot study 
with a small sample size.
Differences in Various assessments
We detected an inconsistency between the results based 
on the existing scales, e.g., the CARS or IRSA, and a newly 
designed, but not yet validated, method of assessing real-life 
social interactions. The negative findings on the former scales 
could partially be attributed to the low sensitivity of these 
assessments, which are based on observation, the low dose of 
OXT or the small sample size. However, the positive findings 
using the latter method were obtained from behaviors that were 
unintentionally noticed by evaluators or caregivers. Our results 
are consistent with the report by Dadds et al. in which a study 
staff individual could reliably guess the chances of whether 
participants had received OXT or the placebo, although there 
were no significant differences in any of the measured outcomes 
(46). Thus, these results suggest that there may be a measure-
ment that is capable of detecting behavioral changes induced by 
OXT. In future studies, it will be necessary to standardize the 
behavior scales observed by family and care givers to further 
develop this new approach.
The findings in this study in favor of OXT have been obtained 
by measurements that draw on lists of reciprocal social interac-
tions through various events, both in daily life and in play ses-
sions. This is not surprising because this observation is assessed 
by bidirectionality, an intrinsic nature of reciprocal social interac-
tions. The theoretical basis for this is that, according to the study 
by Lombardo and Baron-Cohen (47), social interactions with 
others imply bidirectional processes. Perceptions of others partly 
determine how one perceives oneself and perceptions of oneself 
have an impact on how one perceives others. Furthermore, many 
studies have indicated a lack or diminution of self-awareness in 
individuals with ASD (48, 49). Importantly, we know that social 
interactions with an ASD individual would not be bidirectional 
for a typically developing individual. In this sense, “social deficits” 
can indicate the difficulties that typically developing individuals 
encounter in interacting with ASD individuals. Given that OXT 
affects self-awareness (50), OXT could produce bidirectional 
aspects of relationships that emerge not in the whole but in parts 
of daily life, which seems to be difficult to measure with conven-
tional scales, as indicated in this study.
comparison with recent clinical Trials
Currently, there are several reports of clinical trials on repeated 
application of OXT and reviews of these clinical trials. 
Randomized controlled trials reveal potentially promising find-
ings in measures of emotion and eye gaze, which are impaired 
early in the course of ASD (51). In contrast, ASD participants who 
received OXT showed no benefit following treatment on primary 
or secondary outcomes, although caregivers who believed their 
wards received OXT report greater improvements (28). Long-
term OXT administration results in improved scores on the 
communication and social interaction domains of the ADOS-G 
and positive effects on quality of reciprocal communication (52). 
Over 12 weeks of treatment, several measures of social cognition/
function, repetitive behaviors, and anxiety show susceptibility to 
change (18). In addition, as crosstalk exists between vasopressin 
and OXT receptors, the OXT effects for ASD patients should be 
considered with regard to the vasopressin system (53).
Placebo effects
The possible efficacy of OXT in the current result may have been 
masked by placebo effects. Improvements were found in both the 
OXT and placebo phases when evaluated using the CARS, CGI-I, 
and ABC (Figures 4A–C). In contrast, the scores on the IRSA, 
evaluated by independent raters using video images, showed only 
a few changes (Figure 4D). These effects seem to be artifacts of 
the placebo, judging from the results of a previous study that 
found a significant main effect for time and no main effect for 
treatment (46). The staff and caregivers in the current study 
seemed to adequately perform their duties. Thus, it was conceiv-
able that the expectation of beneficial effects of OXT under good 
participant–clinician relationships produced placebo responses 
(54, 55).
Plasma OXT concentrations
We found positive correlations between the plasma OXT con-
centrations and the baseline severity of aberrant behaviors. This 
observation is in agreement with the previous result that higher 
OXT levels were more correlated with developmental delays in 
individuals with ASD (56). In addition, a significant correlation 
between the basal OXT levels and the baseline ratings of the 
Yale–Brown Obsessive-Compulsive Scale has been demonstrated 
in individuals with obsessive-compulsive disorder (57), which 
sometimes co-occurs with ASD (58). Altogether, the current 
study indicates that ASD individuals with lower plasma OXT 
concentrations may show greater responses to external OXT 
through nasal administration and suggests that OXT may have 
modulated novel social interactions. Monitoring OXT concentra-
tions in future trials would be indispensable to improving our 
understanding of this phenomenon.
Here, we measured the OXT concentration in the unextracted 
plasma throughout the experiments using the old version of the 
Assay Designs’ OXT assay kit (currently, Enzo’s EIA kit), as we 
previously reported (37). Recently, the manufacturer’s protocol 
recommends performing the assay in fractioned plasma to 
increase the specificity and sensitivity of the anti-OXT antibody. 
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Thus, the OXT level in the unextracted plasma, which is unmasked 
by the plausible OXT binding proteins, is usually estimated to 
be higher by 3- to 10-fold (59, 60). This point should be further 
explored in future studies.
adverse effects of OXT
Although few adverse events were observed in the study, the 
seizures that occurred in one participant should be discussed. 
Anagnostou et  al. reported that one participant with stable 
epilepsy had staring spells 4 weeks following OXT administra-
tion and discontinued the intervention (27). However, the 
anticonvulsive effect of OXT has also been demonstrated (61). 
Therefore, whether the seizures in our study were caused by OXT 
remains unclear, although we cannot neglect the possibility of 
OXT-induced seizures. Future studies are necessary to examine 
the occurrence of seizures during long-term OXT administra-
tion. Closer attention should be paid to ASD in future trials of 
OXT, especially in patients with ID, because the prevalence of 
epilepsy has been estimated to be 46.0% in ASD individuals with 
IQs below 50 (30).
limitations
First, the limitations of this study include the standard limita-
tions of the randomized, double-blind, and placebo-controlled 
crossover study design. Some participants were included who 
should not have been eligible for participation in ordinary 
randomized, controlled trials, e.g., subjects receiving psy-
chotropic medications, with comorbid epilepsy or medically 
serious conditions. Furthermore, we were unable to determine 
the required sample size in February 2012 when the study was 
registered. Given the effect size (Cohen’s d =  0.57) available 
now (23), the minimum sample size is estimated to be 82 
(parameters: α, 0.05; power, 0.80). Thus, the insignificant dif-
ference observed in this study could be attributable to the small 
sample size of 30.
Second, when we designed this study, we understood that 
we needed an efficient tool to measure patients’ social interac-
tion at their home. However, because we had no knowledge of 
any appropriate questionnaires or other methods to assess this 
parameter, we did not include behavioral analysis at home in the 
secondary outcomes. Subsequently, we intended to use the medi-
cal charts for this aspect, as had been described in the original 
protocol. Recently, we found such a questionnaire, called the 
Home Situations Questionnaire for Autism Spectrum Disorder, 
does exist (62, 63). The current real-life assessment of reciprocal 
social interactions that has not been adequately validated is thus 
the exploratory analysis. Given that it is difficult to detect changes 
caused by treatment through observation, we must use the Home 
Situations Questionnaire or develop other measurements, bear-
ing in mind the unique characteristics of social interaction in 
future studies.
Third, it is uncertain whether the treatment drugs were sprayed 
sufficiently deep into the nasal cavity. Sixteen IUs of OXT may 
have been a low dose compared with that used in previous studies 
(i.e., 48 IU). As previous studies have suggested a dose–response 
phenomenon in the effects of OXT, the negative findings about 
OXT effects on the primary and secondary endpoints might be 
attributable to the relatively low dose of OXT used in this study 
[see Ref. (53)]. However, we chose the dose because we assumed 
that one spray in each nostril every morning and evening would 
be easy for participants with ID to perform. Moreover, it was 
safe to prescribe lower doses of a trial medication, as none of us 
knew the details of the adverse effects of OXT. None of the par-
ticipants were reported to be reluctant to receive the treatment. 
Considering that blood was sampled approximately 6 h or more 
after spraying in the morning, the plasma OXT concentrations 
may not have indicated whether the spraying procedures were 
correctly followed (64–66).
Fourth, we used a single study setting, including the dose and 
duration of OXT administration, which may not be enough to 
elicit significant results. Presently, the ideal study conditions have 
yet to be identified, but we are on the way to contributing to this 
knowledge base. Specially, no applicable prior studies among 
ASD patients with ID were identified.
cOnclUsiOn
This pilot study suggests that long-term administration of 
intranasal OXT would be tolerable for ASD patients with ID 
under careful supervision for the adverse events reported herein, 
including seizures. The results should be considered for reference 
only due to the limitations of this study, although they suggest 
that a new scale should be designed to assess sociability symptom 
changes elicited by OXT administration for ASD patients with ID.
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